Quinn Opportunity Partners LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,000 shares of the biopharmaceutical company’s stock after purchasing an additional 8,000 shares during the period. Gilead Sciences accounts for 0.8% of Quinn Opportunity Partners LLC’s investment portfolio, making the stock its 29th largest holding. Quinn Opportunity Partners LLC’s holdings in Gilead Sciences were worth $4,459,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. Legal & General Group Plc boosted its stake in Gilead Sciences by 9.3% during the 2nd quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock worth $495,778,000 after purchasing an additional 596,992 shares during the period. AQR Capital Management LLC boosted its stake in Gilead Sciences by 25.7% during the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after purchasing an additional 1,066,172 shares during the period. Swiss National Bank boosted its stake in Gilead Sciences by 2.3% during the 2nd quarter. Swiss National Bank now owns 4,775,524 shares of the biopharmaceutical company’s stock worth $338,012,000 after purchasing an additional 107,400 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in Gilead Sciences by 6.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 4,706,832 shares of the biopharmaceutical company’s stock worth $333,150,000 after purchasing an additional 302,787 shares during the period. Hedge funds and other institutional investors own 74.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Quinn Opportunity Partners LLC Acquires 8,000 Shares of Gilead Sciences, Inc. (GILD)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/13/quinn-opportunity-partners-llc-acquires-8000-shares-of-gilead-sciences-inc-gild.html.

In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock worth $36,269,486 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Several analysts have recently commented on GILD shares. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank Of Canada started coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They issued an “outperform” rating and a $94.00 target price for the company. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Leerink Swann restated a “hold” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $85.92.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.77 on Monday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The stock has a market cap of $96,363.46, a P/E ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the company earned $2.75 earnings per share. The company’s quarterly revenue was down 13.2% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is presently 23.69%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.